High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

PASZEKOVÁ Helena KRYUKOV Fedor KUBICZKOVÁ Lenka HÁJEK Roman ŠEVČÍKOVÁ Sabina

Rok publikování 2014
Druh Článek v odborném periodiku
Časopis / Zdroj Clinical lymphoma, myeloma & leukemia
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1016/j.clml.2013.09.004
Obor Onkologie a hematologie
Klíčová slova Cytogenetics; GEP; High-risk disease; MGUS; Multiple myeloma; Prognosis
Popis Multiple myeloma (MM) is a clonal plasma cell malignancy. Although MM is still not completely curable, it can be maintained at the level of a long-term chronic condition. Irrespective of the treatment strategy, relapse is still a major problem for most patients. Approximately 10% to 15% of all MM patients relapse early and have poor prognosis and outcome. Currently, there are many ways of identifying these high-risk patients using cytogenetics or molecular biology. Despite these various approaches to definition of high risk patients, a clear definition of high-risk MM has not been widely accepted. In this review, we discuss and compare various approaches, and their strengths and weaknesses in early identification of high-risk MM patients.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.